Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guys what is the potential on this company?
AIM
AIM ImmunoTech Inc
0.265
-0.0508 (-16.09%)
Volume: 527,731
Day Range: 0.261 - 0.3223
Last Trade Time: 12:49:35 PM EDT
Total Trades: 888
AIM
AIM ImmunoTech Inc
0.67
0.052 (8.41%)
Volume: 150,500
Day Range: 0.607 - 0.68
Last Trade Time: 8:00:00 PM EDT
AIM
AIM ImmunoTech Inc
0.488
-0.032 (-6.15%)
Volume: 176,585
Day Range: 0.48 - 0.5387
Last Trade Time: 8:00:00 PM EDT
AIM
AIM ImmunoTech Inc
0.4784
0.00 (0.00%)
Volume: 61,433
Day Range: 0.475 - 0.50
Last Trade Time: 8:00:00 PM EDT
AIM
AIM ImmunoTech Inc
0.5063
0.0263 (5.48%)
Volume: 62,250
Day Range: 0.47 - 0.49
Last Trade Time: 8:00:00 PM EDT
AIM
AIM ImmunoTech Inc
0.47
0.029 (6.58%)
Volume: 26,623
Day Range: 0.4301 - 0.4586
Last Trade Time: 8:00:00 PM EDT
AIM
AIM ImmunoTech Inc
0.53
0.035 (7.07%)
Volume: 292,608
Day Range: 0.4916 - 0.55
Last Trade Time: 8:00:00 PM EST
AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST
AIM
AIM ImmunoTech Inc
0.60
0.06 (11.11%)
Volume: 98,976
Day Range: 0.5301 - 0.5779
Last Trade Time: 8:00:00 PM EST
They have one fda approved drug patent has expired and Ampligen has been denied by fda. This is a good one one to get in after the rs and wait for the bottom. Just like Maple oil
This company looks like they have some good potential. I recently watched a doctor from Canada who is convinced by her teams studies that the Covid vaccines cause damage to TLRs 3,7, and 8 causing people to be more susceptible to illness. Their TLR 3 nasal spray might be extremely helpful in this case.
AIM
AIM ImmunoTech Inc
0.34
-0.0067 (-1.93%)
Volume: 196,446
Day Range: 0.322 - 0.35
Last Trade Time: 8:00:00 PM EST
AIM
AIM ImmunoTech Inc
0.6286
0.0708 (12.69%)
Volume: 176,005
Day Range: 0.5678 - 0.5797
Last Trade Time: 8:00:00 PM EDT
Total Trades: 323
AIM Detailed Quote
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
This is the AIM I see...
AIM
Bid: 0.70 Ask: 0.7089 Last: 0.7001 Chg ($): -0.0025 Vol: 20.03K
https://finviz.com/quote.ashx?t=AIM
dis is good stuff Phase 2 Study of Ampligen®
Aug-18-22 09:05AM
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
GlobeNewswire
Aug-16-22 04:05PM
AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation
GlobeNewswire
-5.50%
Aug-15-22 04:05PM
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
Business Wire
08:05AM
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
GlobeNewswire
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
lot in pipeline too
Haven't even really started my DD and the first thing that caught my eye was drama!
Quote:
“The actions of AIM are a desperate attempt and part of a troubling pattern of
AIM CEO Tom Equels and directors William Mitchell and Stewart Appelrouth
wasting corporate assets at the expense of stockholders to do whatever it takes
to ensure that they run unopposed, including crafting up ‘conspiracy theories’ in
their effort to retain control and enrich themselves and deny stockholders basic rights to nominate alternative directors,
solely to keep their gravy-train of excessive compensation going,
” stated Mr. Jorgl. “
We are very pleased that the court has set the earliest date possible for expedited proceedings on our matter, which we expect will result in our nominations being allowed.”
https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html
This could get interesting. Going to do some digging and put this on radar.
Just stumbled on this one Mick.
Haven't even really started my DD and the first thing that caught my eye was drama!
https://finance.yahoo.com/news/aim-stockholder-full-value-committee-200500232.html
This could get interesting. Going to do some digging and put this on radar.
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series • GlobeNewswire Inc. • 07/14/2022 12:05:00 PM
Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 07/01/2022 08:32:31 PM
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing • GlobeNewswire Inc. • 06/21/2022 12:35:00 PM
AIM
Aerosonic Common Stock ($0.40 Par Value)
3.19
0.00 (0.00%)
Volume: -
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
0.94 ? 0.02 (2.17%)
Volume: 49,334 @06/03/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 0.91 - 0.93
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
1.06 ? 0.01 (0.95%)
Volume: 115,978 @04/29/22 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.03 - 1.08
AIM Detailed Quote
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided a summary of clinical data that support the synergistic potential of Ampligen® (rintatolimod) with checkpoint blockade therapies.
Thomas Equels, Chief Executive Officer of AIM, commented, “We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions. These data have not only affirmed but significantly evolved our belief that Ampligen as a single agent therapy, as well as in combination with the latest powerful cancer therapies, has the potential to become a breakthrough therapy for some of the most difficult to treat and deadly cancers. We are going to continue working tirelessly to advance Ampligen towards approval and commercialization with the goal of bringing much needed hope to patients and solutions to treating physicians around the world.”
Ampligen is the Company’s dsRNA drug currently being developed for globally important cancers. Ampligen has shown therapeutic synergy with checkpoint inhibitors, including increasing survival rates and efficacy, in the treatment of animal tumors when used in combination with checkpoint blockade therapies. The first detection of Ampligen’s synergistic potential with checkpoint blockade therapeutics was witnessed in pre-clinical mouse models of melanoma and pancreatic cancers. Additionally, the Company now has data from two clinical studies — in advanced recurrent ovarian cancer and triple negative breast cancer — that indicate that the drug may have similar anti-tumor activity in humans.
“Working with AIM, our Pancreatic Cancer R&D team at the Buffett Cancer Center did extensive pre-clinical research demonstrating in animal models that Ampligen had a significant therapeutic benefit in treating pancreatic cancer. This March, Prof. C.H.J. van Eijck and his team at Erasmus MC published data in the journal Cancers showing Ampligen alone was associated with extended overall survival in late-stage pancreatic cancer of 19 months. Just last week, at AACR, publications of clinical data by UPMC’s Dr. Bob Edwards in advanced recurrent ovarian cancer, and Roswell’s Dr. Pawel Kalinski in both stage 4 triple negative breast cancer and stage 4 colorectal cancer, strongly supported the advance of Ampligen into human trials for patients in pancreatic and other cancers where checkpoint drugs are not effective,” stated Michael (Tony) Hollingsworth, PhD, Associate Director, Basic Research, University of Nebraska Medical Center.
“Checkpoint drugs are powerful and important therapies, but only work on ‘hot’ tumors visible to the immune system, not ‘cold’ tumors that are immune-silent. Ampligen appears, from these data, to turn cold tumors into hot tumors and create significant therapeutic potential for a successful second round of Ampligen plus checkpoint therapy for those who do not respond to checkpoint therapy alone,” added Robert Edwards, MD, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute.
“The two ongoing Roswell Park clinical trials we recently presented findings from represent milestones in our 10-year-long NIH and DoD-funded research program aiming to convert immuno-resistant ‘cold’ tumors into ‘hot’ ones that would be more sensitive to immunotherapy. Seeing both studies successfully meet their predetermined efficacy endpoint — selective increase of cytotoxic T lymphocyte markers in tumor tissues — Roswell Park plans to move forward with critical studies assessing therapeutic efficacy of the combination of a rintatolimod-based chemokine-modulating regimen with PD-1 inhibitors, cancer vaccines and/or adoptive T cell therapies in solid tumors. Observations from our preclinical studies suggest that this multipronged strategy may benefit patients with multiple solid-tumor lesions, which are difficult to target individually,” commented Pawel Kalinski, MD, PhD, Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology and Senior Vice President for Team Science at, Roswell Park Comprehensive Cancer Center.
Recurrent Ovarian Cancer: ClinicalTrials.gov: NCT03734692
The investigator-initiated, Phase 2, single-arm, efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (KEYTRUDA®) (IVP) for patients with recurrent platinum-sensitive ovarian cancer is being conducted by the University of Pittsburgh Medical Center (UPMC). The Phase 2 trial is designed to enroll up to 45 subjects using Ampligen in combination with pembrolizumab to test the combinational activity of checkpoint blockade therapy where Ampligen is administered by injection in the peritoneal cavity where the tumor is located.
The Company’s recently announced positive interim results suggesting induction of T cell activation together with clinical responses may indicate prognostic evidence of tumor environment reprogramming that we do not see with chemotherapy alone and which may extend survival. A total of 17 patients have been enrolled and 13 were evaluable for response in the ongoing Phase 2 trial. The observed clinical responses were: 2 complete responses (15.4%), 3 partial responses (23.1%), 3 stable disease (23.1%), 5 progressions (38.4%) for a clinical benefit rate (CR+PR+SD) of 61.6%. From 13 patients, 77 IP wash samples were collected at serial time points. Measurements in IP washes revealed an acute increase in granzyme B (GZMB), perforin, TNF alpha, CXCL9, CXCL10 and CXCL11 after treatment (p<0.05). Longitudinal data revealed a progressive increase in some biomarkers in the locoregional environment; CXCL9, CXCL10, CXCL11, perforin and TNF alpha were all increased from baseline levels at cycle 1 to baseline of cycle 6 (p<0.05). CXCL12 was also increased acutely after treatment (p<0.05).
The cytokine CXCL12 observed to increase acutely after treatment functions as a chemotactic for lymphocytes. The cytokines CXCL9-11 active in antitumor responses in modulation of the tumor microenvironment (TME) to favor cytotoxic T cells required for anti-tumor cell immune activity versus regulatory T cells (Tregs), which function to protect non-tumor “self” tissue. Granzymes are serine proteases released by cytoplasmic granules within cytotoxic T cells and natural killer (NK) cells. They induce programmed cell death (apoptosis) in the target cell, eliminating cells that have become cancerous. Perforin is a protein, which creates tubules in the cell membrane allowing cell lysis. Perforin is a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.
AIM ImmunoTech Inc (AIM)
0.839899 ? -0.000001 (-0.00%)
Volume: 152,721 @03/11/22 8:00:00 PM EST
Bid Ask Day's Range
- - 0.8054 - 0.86
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
0.79 ? 0.0109 (1.40%)
Volume: 85,652 @02/04/22 8:00:00 PM EST
Bid Ask Day's Range
- - 0.789951 - 0.8191
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
1.77 ? -0.01 (-0.56%)
Volume: 243,646 @11/05/21 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.74 - 1.79
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
2.0001 ? -0.0699 (-3.38%)
Volume: 379,977 @09/22/21 7:19:50 PM EDT
Bid Ask Day's Range
- - 1.97 - 2.06
AIM Detailed Quote
AIM ImmunoTech Inc (AIM)
2.03 ? 0.03 (1.50%)
Volume: 239,934 @08/13/21 8:00:00 PM EDT
Bid Ask Day's Range
- - 1.98 - 2.01
AIM Detailed Quote
Sign this petition for Ampligen approval
http://chng.it/ntCkN45ppP
AIM seems to have a hand off drug Ampligen, tested decades ago by other companies:
https://en.wikipedia.org/wiki/Rintatolimod
AIM may be in a chart ready technical phase ready to soar, and I am always ready to applaud the perfect timing of that thrilling prediction.
But in spite of that I recognize AIM's drug approval endeavors as proof of my 2 points:
........That no one can prove a drug will ever be a total failure. All studies of a drug may not have provided the proper conditions to test it for any ultimate endpoint statistical acceptance favoring FDA approval...... Other possible drug trials failures include:
Improper selection of the patients with the most susceptible bio markers.
Improper dosage.
Failure to dose after patient has been conditioned with other therapies as heat, cold, or in drug combination before or after the applications of the combination drug or cocktail.
Etc,etc, etc.
Armed with an infinity of possible reasons for a drug failure such a Company hires experts in PR's to promote the wording of forthcoming positive hopeful conclusions.....headline sound bites will make the stock rise, and the hired experts stand by with ready vigilance to float and dilute at the inflated prices, till stock falls under $1 on sell-offs, until new R/S's sizes it back to harken to the low float crowd, primed ready to continue serving the wash and rinse process, on hopes they can capture the meat before its ultimate trip on the conveyer belt of dreamy expectations, or total failure..
just a question why 9094 shares show up 5 times
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2076
|
Created
|
04/27/12
|
Type
|
Free
|
Moderators |
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers,
as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids
and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon N Injection® (Interferon Alfa-N3).
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory (resistant to other treatment)
or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
We operate a 30,000 sq. ft. facility in New Brunswick, NJ with the objective of producing Ampligen® and Alferon®.
We are committed to a focused business plan oriented toward finding senior co-development partners with the capital and
expertise needed to commercialize the many potential therapeutic aspects of Ampligen® and our FDA-approved drug Alferon® N.
April 4th, 2019
CEO Roadshow Interviews Hemispherx Thomas K. Equels Hemispherx CEO Thomas K. Equels recently sat down with Mike Elliot of CEO Roadshow to provide an update on everything the company is working at [...]
March 25th, 2019
Introducing You to the First Ampligen Quarterly Update Today we announced significant progress in our Ampligen pancreatic cancer program and our multiple Ampligen plus checkpoint blockade immuno-oncology programs. We also announced the [...]
March 9th, 2020
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus
On March 9 th we announced that Japan’s National Institute of Infectious [...]
https://aimimmuno.com/all-articles/
AIM ImmunoTech Describes Their Approach and Progress with Ampligen to Combat COVID-19 SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. Watch the full video here. [...]
AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]
AIM ImmunoTech Reaches Deal with Japan's National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus On March 9 th we announced that Japan’s National Institute of Infectious [...]
Ampligen® represents an RNA being developed for globally important cancers, viral diseases and disorders of the immune system.
Ampligen® has in the clinic demonstrated the potential for standalone efficacy in a number of solid tumors.
We have also seen success in increasing survival rates and efficacy in the treatment of animal tumors when
Ampligen® is used in combination with checkpoint blockade therapies.
This success in the field of immuno-oncology has guided our focus toward the potential use of Ampligen®
as a combinational therapy for the treatment of a variety of solid tumor types.
There are currently multiple Ampligen® clinical trials — both underway and planned — at major cancer research centers around the country.
Ampligen ® is also being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
Ampligen® is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). AIM ImmunoTech
is currently sponsoring an expanded access program (EAP) for ME/CFS patients in the U.S.
In August 2016, we received approval of our NDA from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)
for commercial sale of Ampligen® in the Argentine Republic for the treatment of severe CFS. With regulatory approval in Argentina,
Ampligen® is the world’s only approved therapeutic for ME/CFS.
We continue to pursue our Ampligen New Drug Application, or NDA, for the treatment of CFS with the Food and Drug Administration, or FDA.
Alferon N Injection® is approved for a category of STD infection and patients that are intolerant to recombinant interferon in Argentina.
Alferon is the only natural-source, multi-species alpha interferon currently approved for sale in the U.S. for the intralesional treatment of refractory
(resistant to other treatment) or recurring external Condylomata Acuminata/genital warts (GW) in patients 18 years of age or older.
Certain types of human papilloma viruses cause GW. AIM ImmunoTech also has approval from ANMAT for the treatment of
refractory patients that failed or were intolerant to treatment with recombinant interferon in Argentina.
We have developed and, with proper funding, will be seeking FDA Pre-Approval Inspection of a high-volume, high-efficiency,
upgraded manufacturing process to allow for the commercial viability of Alferon®.
Pipeline
https://aimimmuno.com/pipeline/
Please direct your inquiries regarding business development and licensing opportunities to: info@AIMImmunoTech.com
2117 SW Highway 484
Ocala, FL 34473
Book/sh | 1.96 |
Cash/sh | 0.84 |
Debt/Eq | 0.19
|
Shs Outstand | 32.62M |
Shs Float | 28.77M |
Short Float | 5.87% |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |